Author: Liu, Jia; Li, Kang; Cheng, Lin; Shao, Jingjin; Yang, Shukun; Zhang, Wei; Zhou, Guangqian; de Vries, Antoine A.F.; Yu, Zhiyi
Title: A high-throughput drug screening strategy against coronaviruses Cord-id: qpyupuch Document date: 2020_12_14
ID: qpyupuch
Snippet: The emergence and re-emergence of coronaviruses (CoV) continually cause circulating epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. The resultant disease, coronavirus disease 2019 (COVID-19), has rapidly developed into a worldwide pandemic, leading to severe health and economic burdens. Although the recently announced vaccines against COVID-19 has rekindled hope, there is still a major challenge to urgently meet the global need for rapid trea
Document: The emergence and re-emergence of coronaviruses (CoV) continually cause circulating epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. The resultant disease, coronavirus disease 2019 (COVID-19), has rapidly developed into a worldwide pandemic, leading to severe health and economic burdens. Although the recently announced vaccines against COVID-19 has rekindled hope, there is still a major challenge to urgently meet the global need for rapid treatment of the pandemic. Given the urgency of the CoV outbreak, we propose a strategy to screen potential broad-spectrum drugs against CoV in a high-throughput manner, particularly against SARS-CoV-2. Since the essential functional domains of CoV are extensively homologous, the availability of two types of mild CoV, HCoV-OC43 and MHV, should provide a valuable tool for the rapid identification of promising drugs against CoV without the drawbacks of level three biological confinements. The luciferase reporter gene is introduced into HCoV-OC43 and MHV to indicate viral activity, and hence the antiviral efficiency of screened drugs can be quantified by luciferase activity. Compounds with antiviral activity against both HCoV-OC43 and MHV are further evaluated in SARS-CoV-2 after structural optimizations. This system allows large-scale compounds to be screened to search for broad-spectrum drugs against CoV in a high-throughput manner, providing potential alternatives for clinical management of SARS-CoV-2 or other CoV.
Search related documents:
Co phrase search for related documents- accessory protein and acute cov infection: 1, 2
- accessory protein and addition time: 1, 2
- accessory protein and live virus: 1, 2
- accessory protein and lung damage: 1
- accessory protein and magnetic resonance: 1
- action mechanism and acute cov infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and addition time assay: 1, 2
- action mechanism and live virus: 1, 2
- action mechanism and low toxicity: 1, 2, 3, 4, 5, 6, 7
- action mechanism and luciferase activity: 1
- action mechanism and luciferase gene: 1, 2
- action mechanism and luciferase reporter: 1, 2, 3, 4, 5, 6
- action mechanism and luciferase reporter gene: 1, 2
- action mechanism and lung damage: 1, 2, 3, 4, 5, 6
- action mechanism and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date